The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study
This is a prospective, multicenter, randomized controlled clinical study to evaluate the effect of using intelligent patient management system on medication adherence of HER2 positive breast cancer patients receiving pyrotinib treatment. Pyrotinib is a small molecule tyrosine kinase inhibitor that can irreversibly inhibit HER1, HER2, and HER4.
• Female patients aged ≥ 18 years.
• Histologically confirmed HER2-positive breast cancer (IHC 3+ or IHC 2+ with ISH+).
• Patients expected to receive pyrotinib-containing regimens for neoadjuvant therapy or metastatic/unresectable breast cancer.
• ·≤1 prior line of anti-HER2 therapy during the recurrent/metastatic stage.
• Ability to operate a mobile phone and read independently.
• Deemed psychologically and physically suitable for participation by the investigator.